199 related articles for article (PubMed ID: 22532874)
41. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes.
Lee SH; Che X; Jeong JH; Choi JY; Lee YJ; Lee YH; Bae SC; Lee YM
J Biol Chem; 2012 Apr; 287(18):14760-71. PubMed ID: 22351759
[TBL] [Abstract][Full Text] [Related]
42. Role of exon 2-encoded beta -domain of the von Hippel-Lindau tumor suppressor protein.
Bonicalzi ME; Groulx I; de Paulsen N ; Lee S
J Biol Chem; 2001 Jan; 276(2):1407-16. PubMed ID: 11024059
[TBL] [Abstract][Full Text] [Related]
43. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
44. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
45. Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha.
André H; Pereira TS
J Biol Chem; 2008 Oct; 283(43):29375-84. PubMed ID: 18694926
[TBL] [Abstract][Full Text] [Related]
46. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities.
Galdeano C; Gadd MS; Soares P; Scaffidi S; Van Molle I; Birced I; Hewitt S; Dias DM; Ciulli A
J Med Chem; 2014 Oct; 57(20):8657-63. PubMed ID: 25166285
[TBL] [Abstract][Full Text] [Related]
47. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
48. PHD3 inhibits cell proliferation through hydroxylation of PAX2 at proline 9.
Lun J; Wang Y; Gao Q; Wang Y; Zhang H; Fang J
Acta Biochim Biophys Sin (Shanghai); 2022 May; 54(5):708-715. PubMed ID: 35920196
[TBL] [Abstract][Full Text] [Related]
49. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
Kapitsinou PP; Haase VH
Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
[TBL] [Abstract][Full Text] [Related]
50. Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction.
Buckley DL; Van Molle I; Gareiss PC; Tae HS; Michel J; Noblin DJ; Jorgensen WL; Ciulli A; Crews CM
J Am Chem Soc; 2012 Mar; 134(10):4465-8. PubMed ID: 22369643
[TBL] [Abstract][Full Text] [Related]
51. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.
Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940
[TBL] [Abstract][Full Text] [Related]
52. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
[TBL] [Abstract][Full Text] [Related]
53. Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.
Okumura F; Joo-Okumura A; Nakatsukasa K; Kamura T
PLoS One; 2017; 12(4):e0175593. PubMed ID: 28394947
[TBL] [Abstract][Full Text] [Related]
54. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.
Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC
Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766
[TBL] [Abstract][Full Text] [Related]
55. The Roles of VHL-Dependent Ubiquitination in Signaling and Cancer.
Zhang Q; Yang H
Front Oncol; 2012; 2():35. PubMed ID: 22649785
[TBL] [Abstract][Full Text] [Related]
56. Design and analysis of a Petri net model of the Von Hippel-Lindau (VHL) tumor suppressor interaction network.
Minervini G; Panizzoni E; Giollo M; Masiero A; Ferrari C; Tosatto SC
PLoS One; 2014; 9(6):e96986. PubMed ID: 24886840
[TBL] [Abstract][Full Text] [Related]
57. The multifaceted von Hippel-Lindau tumour suppressor protein.
Robinson CM; Ohh M
FEBS Lett; 2014 Aug; 588(16):2704-11. PubMed ID: 24583008
[TBL] [Abstract][Full Text] [Related]
58. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
59. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
60. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Pugh CW; Ratcliffe PJ
Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]